Clinical Progression on CDR-SB © : Progression Free Time at Each 0.5-unit Level in Dominantly Inherited and Sporadic Alzheimer’s Disease Populations
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
INTRODUCTION
CDR-SB is a reliable and clinically meaningful composite for assessing treatment effects in Alzheimer’s disease (AD) clinical trials. Small CDR-SB differences at the end of a trial often lead to controversy in deriving clinically meaningful interpretations.
METHODS
We estimated progression-free time participants remained at each 0.5-unit CDR-SB increment in dominantly inherited AD (DIAD) and sporadic AD populations, evaluating its potential as an alternative measure of treatment effects.
RESULTS
Progression-free time is longer at CDR-SB ≤ 2.0 (1–2 years) and shorter at CDR-SB ≥ 5 (0.33 or less) in the ADNI cohort. The DIAD cohort showed similar but shorter times. Using progression-free time, continuous lecanemab treatment for three years is estimated to delay disease progression by 0.7 years in the sporadic population.
DISCUSSION
Progression-free time provides a benchmark for expressing clinical progression and treatment effects and can be applied particularly during open-label extensions and singlearm trials without placebo comparisons.
